Forte D.; Barone M.; Morsiani C.; Simonetti G.; Fabbri F.; Bruno S.; Bandini E.; Sollazzo D.; Collura S.; Deregibus M.C.; Auteri G.; Ottaviani E.; Vianelli N.; Camussi G.; Franceschi C.; Capri M.; Palandri F.; Cavo M.; Catani L., Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease, «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH», 2021, 40, Article number: 49, pp. 49 - 49 [articolo]Open Access
Stanzani M.; Sassi C.; Lewis R.; Sartor C.; Rasetto G.; Cavo M.; Battista G., Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study, «JOURNAL OF INFECTION», 2021, 83, pp. 371 - 380 [articolo]
Auner H.W.; Gavriatopoulou M.; Delimpasi S.; Simonova M.; Spicka I.; Pour L.; Dimopoulos M.A.; Kriachok I.; Pylypenko H.; Leleu X.; Doronin V.; Usenko G.; Hajek R.; Benjamin R.; Dolai T.K.; Sinha D.K.; Venner C.P.; Garg M.; Stevens D.A.; Quach H.; Jagannath S.; Moreau P.; Levy M.; Badros A.; Anderson L.D.; Bahlis N.J.; Facon T.; Mateos M.V.; Cavo M.; Chai Y.; Arazy M.; Shah J.; Shacham S.; Kauffman M.G.; Richardson P.G.; Grosicki S., Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma, «AMERICAN JOURNAL OF HEMATOLOGY», 2021, 96, pp. 708 - 718 [articolo]Open Access
Mateos, M. V.; Gavriatopoulou, M.; Facon, T.; Auner, H. W.; Leleu, X.; Hajek, R.; Dimopoulos, M. A.; Delimpasi, S.; Simonova, M.; Spicka, I.; Pour, L.; Kriachok, I.; Pylypenko, H.; Doronin, V.; Usenko, G.; Benjamin, R.; Dolai, T. K.; Sinha, D. K.; Venner, C. P.; Garg, M.; Stevens, D. A.; Quach, H.; Jagannath, S.; Moreau, P.; Levy, M.; Badros, A. Z.; Anderson, L. D.; Bahlis, N. J.; Cavo, M.; Chai, Y.; Jeha, J.; Arazy, M.; Shah, J.; Shacham, S.; Kauffman, M. G.; Richardson, P. G.; Grosicki, S., Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma, «JOURNAL OF HEMATOLOGY & ONCOLOGY», 2021, 14, Article number: 59, pp. 1 - 5 [articolo]Open Access
Gentile M.; Specchia G.; Derudas D.; Galli M.; Botta C.; Rocco S.; Conticello C.; Califano C.; Giuliani N.; Mangiacavalli S.; Attingenti E.; Lombardo A.; Brunori M.; Rossi E.; Antonioli E.; Ria R.; Zambello R.; Di Renzo N.; Mele G.; Marcacci G.; Musto P.; Capalbo S.; Cascavilla N.; Cerchione C.; Belotti A.; Criscuolo C.; Uccello G.; Curci P.; Vigna E.; Fraticelli V.; Vincelli D.; Bonalumi A.; Siniscalchi A.; Stocchi R.; Martino M.; Ballanti S.; Gangemi D.; Gagliardi A.; Gamberi B.; Pompa A.; Recchia A.G.; Tripepi G.; Pitino A.; Frigeri F.; Consoli U.; Bringhen S.; Zamagni E.; Patriarca F.; De Stefano V.; Di Raimondo F.; Palmieri S.; Petrucci M.T.; Offidani M.; Boccadoro M.; Cavo M.; Morabito F., Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials, «HAEMATOLOGICA», 2021, 106, pp. 291 - 294 [articolo]Open Access
Tacchetti P.; Rocchi S.; Barbato S.; Zamagni E.; Pantani L.; Mancuso K.; Rizzello I.; Cavo M., Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients, «EXPERT REVIEW OF HEMATOLOGY», 2021, 14, pp. 1085 - 1098 [articolo]
Ciciarello M.; Corradi G.; Forte D.; Cavo M.; Curti A., Emerging bone marrow microenvironment‐driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance?, «CANCERS», 2021, 13, Article number: 5319, pp. 5319 - 5319 [articolo]Open Access
Chari A.; Munder M.; Weisel K.; Jenner M.; Bygrave C.; Petrucci M.T.; Boccadoro M.; Cavo M.; van de Donk N.W.C.J.; Turgut M.; Demirkan F.; Karadogan I.; Libby E.; Kleiman R.; Kuppens S.; Bandekar R.; Neff T.; Heuck C.; Qi M.; Clemens P.L.; Goldschmidt H., Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy, «ADVANCES IN THERAPY», 2021, 38, pp. 1328 - 1341 [articolo]
Cavo M.; Tacchetti P.; Zamagni E., Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma, «THE LANCET», 2021, 397, pp. 2311 - 2313 [articolo]
Rosinol L.; Beksac M.; Zamagni E.; Van de Donk N.W.C.J.; Anderson K.C.; Badros A.; Caers J.; Cavo M.; Dimopoulos M.-A.; Dispenzieri A.; Einsele H.; Engelhardt M.; Fernandez de Larrea C.; Gahrton G.; Gay F.; Hajek R.; Hungria V.; Jurczyszyn A.; Kroger N.; Kyle R.A.; Leal da Costa F.; Leleu X.; Lentzsch S.; Mateos M.V.; Merlini G.; Mohty M.; Moreau P.; Rasche L.; Reece D.; Sezer O.; Sonneveld P.; Usmani S.Z.; Vanderkerken K.; Vesole D.H.; Waage A.; Zweegman S.; Richardson P.G.; Blade J., Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, «BRITISH JOURNAL OF HAEMATOLOGY», 2021, 194, pp. 496 - 507 [articolo]
Richardson P.G.; Kumar S.K.; Masszi T.; Grzasko N.; Bahlis N.J.; Hansson M.; Pour L.; Sandhu I.; Ganly P.; Baker B.W.; Jackson S.R.; Stoppa A.-M.; Gimsing P.; Garderet L.; Touzeau C.; Buadi F.K.; Laubach J.P.; Cavo M.; Darif M.; Labotka R.; Berg D.; Moreau P., Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 2430 - 2442 [articolo]
Usmani S.Z.; Mateos M.-V.; Hungria V.; Iida S.; Bahlis N.J.; Nahi H.; Magen H.; Cavo M.; Hulin C.; White D.; De Stefano V.; Fastenau J.; Slavcev M.; Heuck C.; Qin X.; Pei H.; Masterson T.; Lantz K.; Gries K.S., Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2021, 147, pp. 619 - 631 [articolo]
Solimando, Antonio G; Da Vià, Matteo C; Leone, Patrizia; Borrelli, Paola; Croci, Giorgio A; Tabares, Paula; Brandl, Andreas; Di Lernia, Giuseppe; Bianchi, Francesco P; Tafuri, Silvio; Steinbrunn, Torsten; Balduini, Alessandra; Melaccio, Assunta; De Summa, Simona; Argentiero, Antonella; Rauert-Wunderlich, Hilka; Frassanito, Maria A; Ditonno, Paolo; Henke, Erik; Klapper, Wolfram; Ria, Roberto; Terragna, Carolina; Rasche, Leo; Rosenwald, Andreas; Kortüm, K Martin; Cavo, Michele; Ribatti, Domenico; Racanelli, Vito; Einsele, Hermann; Vacca, Angelo; Beilhack, Andreas, Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression, «HAEMATOLOGICA», 2021, 106, pp. 1943 - 1956 [articolo]Open Access
Knop S.; Mateos M.-V.; Dimopoulos M.A.; Suzuki K.; Jakubowiak A.; Doyen C.; Lucio P.; Nagy Z.; Usenko G.; Pour L.; Cook M.; Grosicki S.; Crepaldi A.; Liberati A.M.; Campbell P.; Shelekhova T.; Yoon S.-S.; Losava G.; Fujisaki T.; Garg M.; Wang J.; Wroblewski S.; Kudva A.; Gries K.S.; Fastenau J.; San-Miguel J.; Cavo M., Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial, «BMC CANCER», 2021, 21, Article number: 659, pp. 1 - 14 [articolo]Open Access
Zamagni, Elena; Barbato, Simona; Cavo, Michele, How I Treat High-risk Multiple Myeloma, «BLOOD», 2021, blood.2020008733, pp. N/A - N/A [articolo]
